Welcome to Seeking Alpha's Wall Street Lunch, our afternoon update on today's market action news and analysis.

Good afternoon. Today is Tuesday, November 28th, and I'm your host, Kim Khan. Our top story so far.

Eli Lilly's anti-obesity medication, Terzepitide, is three times more likely to result in a 15% weight reduction compared to Novonordisk's rival therapy

sonaggluteide according to a first of its kind real world study. The study

published on med RX-I-V last week in a

head of a peer review, represented more than 40,000 overweight or obese adults who

started their medications between May 2022 and September 2023.

Noveo's weight loss of diabetes drugs, Wagovi and Ozempick,

consists of semaglutide as the active pharmaceutical ingredient.

Lily's rival therapies, Monjaro. of semagglutide as the active pharmaceutical ingredient.

Lily's rival therapies, Monjaro, and Zeppbound,

consist of Teepetide as the API.

With little or no evidence indicating

the head-to-head efficacy of two of the most popular medications

in the world, Truvita, a collective of U.S. health care systems, conducted the study using

electronic health records and pharmacy dispensing data.

In today's trading, stocks are finding firm direction hard to come by, with housing consumer

sentiment data having little impact.

The major averages are leaning slightly lower, but nothing definitive. The 10-year averages are leaning slightly lower but nothing definitive.

The 10-year Treasury yield is moving lower, under 4.4 percent, after some dovish comments from FOMC Hawk Chris Waller.

Gold continues its upward momentum, and oil is rebounding and reports of potential

further OPEC-plus production cuts. The conference board's Consumer Confidence Index increased

...